nodes	percent_of_prediction	percent_of_DWPC	metapath
Minocycline—VEGFA—Gliclazide—type 2 diabetes mellitus	0.292	0.76	CbGbCtD
Minocycline—CASP3—type 2 diabetes mellitus	0.225	0.522	CbGaD
Minocycline—VEGFA—type 2 diabetes mellitus	0.104	0.243	CbGaD
Minocycline—MMP9—type 2 diabetes mellitus	0.101	0.235	CbGaD
Minocycline—SLC22A7—Glyburide—type 2 diabetes mellitus	0.023	0.0597	CbGbCtD
Minocycline—SLC22A6—Chlorpropamide—type 2 diabetes mellitus	0.0191	0.0496	CbGbCtD
Minocycline—SLC22A6—Tolbutamide—type 2 diabetes mellitus	0.017	0.0442	CbGbCtD
Minocycline—SLC22A6—Nateglinide—type 2 diabetes mellitus	0.0145	0.0376	CbGbCtD
Minocycline—SLC22A6—Glyburide—type 2 diabetes mellitus	0.00977	0.0254	CbGbCtD
Minocycline—CASP3—middle cerebral artery—type 2 diabetes mellitus	0.00954	0.139	CbGeAlD
Minocycline—SLC22A6—Losartan—type 2 diabetes mellitus	0.00893	0.0232	CbGbCtD
Minocycline—MMP9—middle cerebral artery—type 2 diabetes mellitus	0.00635	0.0926	CbGeAlD
Minocycline—MMP9—tunica intima—type 2 diabetes mellitus	0.00397	0.0579	CbGeAlD
Minocycline—IL1B—leg—type 2 diabetes mellitus	0.00298	0.0434	CbGeAlD
Minocycline—IL1B—hindlimb—type 2 diabetes mellitus	0.00266	0.0388	CbGeAlD
Minocycline—MMP9—hindlimb—type 2 diabetes mellitus	0.00222	0.0323	CbGeAlD
Minocycline—CASP3—artery—type 2 diabetes mellitus	0.00204	0.0298	CbGeAlD
Minocycline—CASP3—nerve—type 2 diabetes mellitus	0.00203	0.0295	CbGeAlD
Minocycline—CASP3—endothelium—type 2 diabetes mellitus	0.00172	0.0251	CbGeAlD
Minocycline—IL1B—artery—type 2 diabetes mellitus	0.00163	0.0238	CbGeAlD
Minocycline—IL1B—endothelium—type 2 diabetes mellitus	0.00138	0.0201	CbGeAlD
Minocycline—MMP9—artery—type 2 diabetes mellitus	0.00136	0.0198	CbGeAlD
Minocycline—MMP9—endothelium—type 2 diabetes mellitus	0.00115	0.0167	CbGeAlD
Minocycline—CYCS—islet of Langerhans—type 2 diabetes mellitus	0.00115	0.0167	CbGeAlD
Minocycline—CASP3—islet of Langerhans—type 2 diabetes mellitus	0.000981	0.0143	CbGeAlD
Minocycline—CYCS—retina—type 2 diabetes mellitus	0.000979	0.0143	CbGeAlD
Minocycline—CASP1—cardiovascular system—type 2 diabetes mellitus	0.000861	0.0125	CbGeAlD
Minocycline—CASP1—kidney—type 2 diabetes mellitus	0.000842	0.0123	CbGeAlD
Minocycline—CASP3—retina—type 2 diabetes mellitus	0.000839	0.0122	CbGeAlD
Minocycline—CYCS—cardiovascular system—type 2 diabetes mellitus	0.000828	0.0121	CbGeAlD
Minocycline—CASP1—cortex of kidney—type 2 diabetes mellitus	0.00082	0.0119	CbGeAlD
Minocycline—CYCS—kidney—type 2 diabetes mellitus	0.000811	0.0118	CbGeAlD
Minocycline—CYCS—pancreas—type 2 diabetes mellitus	0.000805	0.0117	CbGeAlD
Minocycline—CASP3—nephron tubule—type 2 diabetes mellitus	0.00079	0.0115	CbGeAlD
Minocycline—IL1B—islet of Langerhans—type 2 diabetes mellitus	0.000784	0.0114	CbGeAlD
Minocycline—Doxycycline—MMP1—type 2 diabetes mellitus	0.000778	0.446	CrCbGaD
Minocycline—VEGFA—islet of Langerhans—type 2 diabetes mellitus	0.000771	0.0112	CbGeAlD
Minocycline—CASP1—adipose tissue—type 2 diabetes mellitus	0.000759	0.0111	CbGeAlD
Minocycline—CASP3—cardiovascular system—type 2 diabetes mellitus	0.00071	0.0103	CbGeAlD
Minocycline—CASP3—kidney—type 2 diabetes mellitus	0.000694	0.0101	CbGeAlD
Minocycline—CASP3—pancreas—type 2 diabetes mellitus	0.00069	0.01	CbGeAlD
Minocycline—CASP3—adipose tissue—type 2 diabetes mellitus	0.000626	0.00912	CbGeAlD
Minocycline—VEGFA—nephron tubule—type 2 diabetes mellitus	0.000621	0.00904	CbGeAlD
Minocycline—IL1B—cardiovascular system—type 2 diabetes mellitus	0.000567	0.00826	CbGeAlD
Minocycline—IL1B—kidney—type 2 diabetes mellitus	0.000555	0.00808	CbGeAlD
Minocycline—IL1B—pancreas—type 2 diabetes mellitus	0.000551	0.00803	CbGeAlD
Minocycline—VEGFA—pancreas—type 2 diabetes mellitus	0.000542	0.0079	CbGeAlD
Minocycline—CASP1—liver—type 2 diabetes mellitus	0.000532	0.00776	CbGeAlD
Minocycline—VEGFA—cortex of kidney—type 2 diabetes mellitus	0.000531	0.00774	CbGeAlD
Minocycline—ALOX5—islet of Langerhans—type 2 diabetes mellitus	0.000516	0.00752	CbGeAlD
Minocycline—CYCS—liver—type 2 diabetes mellitus	0.000512	0.00746	CbGeAlD
Minocycline—IL1B—adipose tissue—type 2 diabetes mellitus	0.0005	0.00728	CbGeAlD
Minocycline—SLC22A11—nephron tubule—type 2 diabetes mellitus	0.000499	0.00726	CbGeAlD
Minocycline—VEGFA—adipose tissue—type 2 diabetes mellitus	0.000492	0.00716	CbGeAlD
Minocycline—MMP9—cardiovascular system—type 2 diabetes mellitus	0.000472	0.00688	CbGeAlD
Minocycline—SLC22A6—nephron tubule—type 2 diabetes mellitus	0.00047	0.00685	CbGeAlD
Minocycline—MMP9—kidney—type 2 diabetes mellitus	0.000462	0.00673	CbGeAlD
Minocycline—MMP9—pancreas—type 2 diabetes mellitus	0.000459	0.00669	CbGeAlD
Minocycline—VEGFA—Glyburide—Tolazamide—type 2 diabetes mellitus	0.000442	0.17	CbGdCrCtD
Minocycline—VEGFA—Glyburide—Glimepiride—type 2 diabetes mellitus	0.000442	0.17	CbGdCrCtD
Minocycline—CASP3—liver—type 2 diabetes mellitus	0.000439	0.00639	CbGeAlD
Minocycline—SLC22A11—kidney—type 2 diabetes mellitus	0.000438	0.00638	CbGeAlD
Minocycline—SLC22A7—kidney—type 2 diabetes mellitus	0.000428	0.00623	CbGeAlD
Minocycline—SLC22A11—cortex of kidney—type 2 diabetes mellitus	0.000427	0.00622	CbGeAlD
Minocycline—VEGFA—Glyburide—Glipizide—type 2 diabetes mellitus	0.000419	0.161	CbGdCrCtD
Minocycline—VEGFA—Glyburide—Gliclazide—type 2 diabetes mellitus	0.000419	0.161	CbGdCrCtD
Minocycline—MMP9—adipose tissue—type 2 diabetes mellitus	0.000417	0.00607	CbGeAlD
Minocycline—SLC22A7—cortex of kidney—type 2 diabetes mellitus	0.000416	0.00607	CbGeAlD
Minocycline—SLC22A6—cortex of kidney—type 2 diabetes mellitus	0.000402	0.00586	CbGeAlD
Minocycline—VEGFA—Glyburide—Chlorpropamide—type 2 diabetes mellitus	0.000383	0.148	CbGdCrCtD
Minocycline—ALOX5—cardiovascular system—type 2 diabetes mellitus	0.000373	0.00544	CbGeAlD
Minocycline—ALOX5—pancreas—type 2 diabetes mellitus	0.000363	0.00529	CbGeAlD
Minocycline—IL1B—liver—type 2 diabetes mellitus	0.000351	0.00511	CbGeAlD
Minocycline—VEGFA—liver—type 2 diabetes mellitus	0.000345	0.00502	CbGeAlD
Minocycline—ALOX5—adipose tissue—type 2 diabetes mellitus	0.000329	0.0048	CbGeAlD
Minocycline—VEGFA—Enalapril—Nateglinide—type 2 diabetes mellitus	0.000306	0.118	CbGdCrCtD
Minocycline—Rolitetracycline—CYP3A4—type 2 diabetes mellitus	0.000301	0.173	CrCbGaD
Minocycline—MMP9—liver—type 2 diabetes mellitus	0.000292	0.00426	CbGeAlD
Minocycline—SLC22A8—nephron tubule—type 2 diabetes mellitus	0.000281	0.0041	CbGeAlD
Minocycline—SLC22A11—liver—type 2 diabetes mellitus	0.000277	0.00404	CbGeAlD
Minocycline—Methacycline—ALB—type 2 diabetes mellitus	0.000275	0.158	CrCbGaD
Minocycline—SLC22A7—liver—type 2 diabetes mellitus	0.00027	0.00394	CbGeAlD
Minocycline—SLC22A8—kidney—type 2 diabetes mellitus	0.000247	0.0036	CbGeAlD
Minocycline—SLC22A8—cortex of kidney—type 2 diabetes mellitus	0.000241	0.00351	CbGeAlD
Minocycline—ALOX5—liver—type 2 diabetes mellitus	0.000231	0.00337	CbGeAlD
Minocycline—VEGFA—Enalapril—Ramipril—type 2 diabetes mellitus	0.000186	0.0716	CbGdCrCtD
Minocycline—Tetracycline—CYP3A4—type 2 diabetes mellitus	0.000138	0.0792	CrCbGaD
Minocycline—Doxycycline—CYP3A4—type 2 diabetes mellitus	0.000131	0.0751	CrCbGaD
Minocycline—Tetracycline—ALB—type 2 diabetes mellitus	0.000121	0.0691	CrCbGaD
Minocycline—MMP9—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	6.83e-06	6.06e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—SPRY2—type 2 diabetes mellitus	6.82e-06	6.06e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	6.82e-06	6.06e-05	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—AVP—type 2 diabetes mellitus	6.79e-06	6.03e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IAPP—type 2 diabetes mellitus	6.79e-06	6.03e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—INSR—type 2 diabetes mellitus	6.74e-06	5.99e-05	CbGpPWpGaD
Minocycline—VEGFA—Focal Adhesion—AKT1—type 2 diabetes mellitus	6.74e-06	5.99e-05	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—AKT1—type 2 diabetes mellitus	6.71e-06	5.96e-05	CbGpPWpGaD
Minocycline—CASP1—Immune System—NFKB1—type 2 diabetes mellitus	6.7e-06	5.95e-05	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—PIK3R1—type 2 diabetes mellitus	6.7e-06	5.95e-05	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—NOS3—type 2 diabetes mellitus	6.7e-06	5.95e-05	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—AKT1—type 2 diabetes mellitus	6.66e-06	5.92e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	6.65e-06	5.91e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—RBP4—type 2 diabetes mellitus	6.65e-06	5.91e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—GLP1R—type 2 diabetes mellitus	6.65e-06	5.91e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—PRKCB—type 2 diabetes mellitus	6.64e-06	5.9e-05	CbGpPWpGaD
Minocycline—SLC22A8—Transmembrane transport of small molecules—PPARA—type 2 diabetes mellitus	6.64e-06	5.89e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—TRPC6—type 2 diabetes mellitus	6.62e-06	5.88e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—ICAM1—type 2 diabetes mellitus	6.61e-06	5.88e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—GNB3—type 2 diabetes mellitus	6.59e-06	5.85e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—AGTR2—type 2 diabetes mellitus	6.59e-06	5.85e-05	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—APOB—type 2 diabetes mellitus	6.57e-06	5.83e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CCKAR—type 2 diabetes mellitus	6.54e-06	5.81e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—AVP—type 2 diabetes mellitus	6.5e-06	5.78e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—MMP3—type 2 diabetes mellitus	6.5e-06	5.78e-05	CbGpPWpGaD
Minocycline—CYCS—Metabolism—PPARG—type 2 diabetes mellitus	6.49e-06	5.77e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IGF2—type 2 diabetes mellitus	6.47e-06	5.75e-05	CbGpPWpGaD
Minocycline—SLC22A11—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	6.47e-06	5.74e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	6.45e-06	5.73e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—RELA—type 2 diabetes mellitus	6.43e-06	5.71e-05	CbGpPWpGaD
Minocycline—CYCS—Metabolism—INS—type 2 diabetes mellitus	6.37e-06	5.66e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—EDNRB—type 2 diabetes mellitus	6.31e-06	5.6e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—APOB—type 2 diabetes mellitus	6.29e-06	5.58e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—IRS1—type 2 diabetes mellitus	6.28e-06	5.58e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IGF1R—type 2 diabetes mellitus	6.26e-06	5.56e-05	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—NFKB1—type 2 diabetes mellitus	6.24e-06	5.55e-05	CbGpPWpGaD
Minocycline—CASP1—Immune System—SRC—type 2 diabetes mellitus	6.24e-06	5.55e-05	CbGpPWpGaD
Minocycline—SLC22A8—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	6.22e-06	5.53e-05	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—EGFR—type 2 diabetes mellitus	6.2e-06	5.51e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—EDN1—type 2 diabetes mellitus	6.19e-06	5.49e-05	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—ADCY5—type 2 diabetes mellitus	6.14e-06	5.45e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—PSMD6—type 2 diabetes mellitus	6.12e-06	5.44e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—HTR2C—type 2 diabetes mellitus	6.12e-06	5.44e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—PPARGC1A—type 2 diabetes mellitus	6.02e-06	5.35e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—GNB3—type 2 diabetes mellitus	6.02e-06	5.35e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—LPL—type 2 diabetes mellitus	6e-06	5.33e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—HMOX1—type 2 diabetes mellitus	5.99e-06	5.32e-05	CbGpPWpGaD
Minocycline—VEGFA—Platelet activation, signaling and aggregation—AKT1—type 2 diabetes mellitus	5.97e-06	5.31e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—EDNRA—type 2 diabetes mellitus	5.96e-06	5.29e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CYBA—type 2 diabetes mellitus	5.93e-06	5.27e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	5.93e-06	5.26e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—CASP8—type 2 diabetes mellitus	5.92e-06	5.26e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—CAT—type 2 diabetes mellitus	5.91e-06	5.25e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IAPP—type 2 diabetes mellitus	5.89e-06	5.23e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—ADCY5—type 2 diabetes mellitus	5.88e-06	5.22e-05	CbGpPWpGaD
Minocycline—SLC22A7—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	5.87e-06	5.21e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—INSR—type 2 diabetes mellitus	5.85e-06	5.2e-05	CbGpPWpGaD
Minocycline—CYCS—Metabolism—ALB—type 2 diabetes mellitus	5.84e-06	5.19e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	5.83e-06	5.18e-05	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—SRC—type 2 diabetes mellitus	5.82e-06	5.17e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—AKT2—type 2 diabetes mellitus	5.82e-06	5.16e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—GHRL—type 2 diabetes mellitus	5.81e-06	5.16e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—PLAT—type 2 diabetes mellitus	5.81e-06	5.16e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—TRPC6—type 2 diabetes mellitus	5.75e-06	5.11e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—APOB—type 2 diabetes mellitus	5.74e-06	5.1e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CALCA—type 2 diabetes mellitus	5.73e-06	5.09e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—AGTR2—type 2 diabetes mellitus	5.72e-06	5.08e-05	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—VEGFA—type 2 diabetes mellitus	5.67e-06	5.03e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	5.63e-06	5e-05	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—IL6—type 2 diabetes mellitus	5.62e-06	4.99e-05	CbGpPWpGaD
Minocycline—CYCS—Metabolism—PIK3R1—type 2 diabetes mellitus	5.59e-06	4.96e-05	CbGpPWpGaD
Minocycline—CYCS—Metabolism—NOS3—type 2 diabetes mellitus	5.59e-06	4.96e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—GSTM1—type 2 diabetes mellitus	5.58e-06	4.96e-05	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—PPARA—type 2 diabetes mellitus	5.54e-06	4.92e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CCR5—type 2 diabetes mellitus	5.53e-06	4.91e-05	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—IL6—type 2 diabetes mellitus	5.49e-06	4.88e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—LPL—type 2 diabetes mellitus	5.48e-06	4.87e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—MMP9—type 2 diabetes mellitus	5.48e-06	4.87e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—EDNRB—type 2 diabetes mellitus	5.48e-06	4.86e-05	CbGpPWpGaD
Minocycline—CASP1—Immune System—EGFR—type 2 diabetes mellitus	5.47e-06	4.86e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—NFKB1—type 2 diabetes mellitus	5.42e-06	4.81e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—C3—type 2 diabetes mellitus	5.4e-06	4.8e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	5.4e-06	4.8e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—ADCY5—type 2 diabetes mellitus	5.37e-06	4.77e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—GPX1—type 2 diabetes mellitus	5.35e-06	4.75e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—PSMD6—type 2 diabetes mellitus	5.32e-06	4.72e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—HTR2C—type 2 diabetes mellitus	5.32e-06	4.72e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—GCG—type 2 diabetes mellitus	5.31e-06	4.72e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—PTPN1—type 2 diabetes mellitus	5.31e-06	4.72e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—PIK3R1—type 2 diabetes mellitus	5.28e-06	4.69e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	5.22e-06	4.64e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—CD36—type 2 diabetes mellitus	5.21e-06	4.63e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	5.21e-06	4.62e-05	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—TGFB1—type 2 diabetes mellitus	5.2e-06	4.62e-05	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	5.2e-06	4.61e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—EDNRA—type 2 diabetes mellitus	5.17e-06	4.59e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—HIF1A—type 2 diabetes mellitus	5.15e-06	4.58e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CYBA—type 2 diabetes mellitus	5.15e-06	4.57e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—PPP2CA—type 2 diabetes mellitus	5.14e-06	4.57e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IRS2—type 2 diabetes mellitus	5.14e-06	4.57e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—AGT—type 2 diabetes mellitus	5.13e-06	4.56e-05	CbGpPWpGaD
Minocycline—CYCS—Metabolism—PTGS2—type 2 diabetes mellitus	5.11e-06	4.54e-05	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—EGFR—type 2 diabetes mellitus	5.1e-06	4.53e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—BCL2—type 2 diabetes mellitus	5.08e-06	4.51e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	5.06e-06	4.49e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—SRC—type 2 diabetes mellitus	5.05e-06	4.49e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CALM1—type 2 diabetes mellitus	5.05e-06	4.48e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—GHRL—type 2 diabetes mellitus	5.04e-06	4.48e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—PLAT—type 2 diabetes mellitus	5.04e-06	4.48e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—LEP—type 2 diabetes mellitus	5.03e-06	4.47e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—APOE—type 2 diabetes mellitus	5.03e-06	4.47e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CALCA—type 2 diabetes mellitus	4.98e-06	4.42e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.97e-06	4.42e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—RELA—type 2 diabetes mellitus	4.97e-06	4.41e-05	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—SRC—type 2 diabetes mellitus	4.96e-06	4.4e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—MTHFR—type 2 diabetes mellitus	4.94e-06	4.38e-05	CbGpPWpGaD
Minocycline—SLC22A8—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	4.93e-06	4.38e-05	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—TNF—type 2 diabetes mellitus	4.86e-06	4.31e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—PPARA—type 2 diabetes mellitus	4.84e-06	4.3e-05	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—IL6—type 2 diabetes mellitus	4.77e-06	4.24e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.74e-06	4.21e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—AGT—type 2 diabetes mellitus	4.69e-06	4.16e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	4.69e-06	4.16e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	4.62e-06	4.1e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—CALM1—type 2 diabetes mellitus	4.61e-06	4.09e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—GCG—type 2 diabetes mellitus	4.61e-06	4.09e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—PTPN1—type 2 diabetes mellitus	4.61e-06	4.09e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—APOE—type 2 diabetes mellitus	4.59e-06	4.08e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—GNB3—type 2 diabetes mellitus	4.58e-06	4.06e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—APOA1—type 2 diabetes mellitus	4.54e-06	4.03e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	4.53e-06	4.03e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	4.52e-06	4.01e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—TGFB1—type 2 diabetes mellitus	4.52e-06	4.01e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—AVP—type 2 diabetes mellitus	4.51e-06	4.01e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—MMP3—type 2 diabetes mellitus	4.51e-06	4.01e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IGF2—type 2 diabetes mellitus	4.49e-06	3.99e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IRS1—type 2 diabetes mellitus	4.49e-06	3.99e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	4.47e-06	3.97e-05	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—TGFB1—type 2 diabetes mellitus	4.43e-06	3.93e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—EGFR—type 2 diabetes mellitus	4.43e-06	3.93e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—APOB—type 2 diabetes mellitus	4.36e-06	3.88e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IGF1R—type 2 diabetes mellitus	4.35e-06	3.86e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—INS—type 2 diabetes mellitus	4.3e-06	3.82e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—EDN1—type 2 diabetes mellitus	4.29e-06	3.81e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CCL2—type 2 diabetes mellitus	4.23e-06	3.76e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—TNF—type 2 diabetes mellitus	4.22e-06	3.75e-05	CbGpPWpGaD
Minocycline—CASP1—Immune System—IL6—type 2 diabetes mellitus	4.21e-06	3.74e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—NFKB1—type 2 diabetes mellitus	4.19e-06	3.72e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—LPL—type 2 diabetes mellitus	4.17e-06	3.7e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.16e-06	3.69e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.15e-06	3.69e-05	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	4.12e-06	3.66e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—ADCY5—type 2 diabetes mellitus	4.08e-06	3.62e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	4.01e-06	3.56e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—PPARG—type 2 diabetes mellitus	4e-06	3.55e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—GNB3—type 2 diabetes mellitus	3.97e-06	3.53e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.95e-06	3.51e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—INS—type 2 diabetes mellitus	3.92e-06	3.49e-05	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—IL6—type 2 diabetes mellitus	3.92e-06	3.48e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—AVP—type 2 diabetes mellitus	3.92e-06	3.48e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—MMP3—type 2 diabetes mellitus	3.92e-06	3.48e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	3.91e-06	3.47e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—SRC—type 2 diabetes mellitus	3.9e-06	3.47e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IGF2—type 2 diabetes mellitus	3.9e-06	3.47e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	3.88e-06	3.45e-05	CbGpPWpGaD
Minocycline—CASP1—Immune System—AKT1—type 2 diabetes mellitus	3.88e-06	3.45e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CCR5—type 2 diabetes mellitus	3.84e-06	3.41e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—APOB—type 2 diabetes mellitus	3.79e-06	3.36e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IGF1R—type 2 diabetes mellitus	3.77e-06	3.35e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.77e-06	3.35e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.77e-06	3.35e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—C3—type 2 diabetes mellitus	3.75e-06	3.33e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—EDN1—type 2 diabetes mellitus	3.73e-06	3.31e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—LPL—type 2 diabetes mellitus	3.62e-06	3.21e-05	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—AKT1—type 2 diabetes mellitus	3.62e-06	3.21e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—ALB—type 2 diabetes mellitus	3.6e-06	3.2e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—HIF1A—type 2 diabetes mellitus	3.58e-06	3.18e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IRS2—type 2 diabetes mellitus	3.57e-06	3.17e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—AGT—type 2 diabetes mellitus	3.56e-06	3.17e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—RELA—type 2 diabetes mellitus	3.55e-06	3.15e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—ADCY5—type 2 diabetes mellitus	3.54e-06	3.14e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CALM1—type 2 diabetes mellitus	3.5e-06	3.11e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—APOE—type 2 diabetes mellitus	3.49e-06	3.1e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—LEP—type 2 diabetes mellitus	3.49e-06	3.1e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—APOA1—type 2 diabetes mellitus	3.45e-06	3.07e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—PIK3R1—type 2 diabetes mellitus	3.44e-06	3.06e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—NOS3—type 2 diabetes mellitus	3.44e-06	3.06e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—EGFR—type 2 diabetes mellitus	3.42e-06	3.04e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—IL6—type 2 diabetes mellitus	3.4e-06	3.02e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	3.39e-06	3.01e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CCR5—type 2 diabetes mellitus	3.33e-06	2.96e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.29e-06	2.93e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—C3—type 2 diabetes mellitus	3.26e-06	2.89e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—PTGS2—type 2 diabetes mellitus	3.15e-06	2.8e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—AKT1—type 2 diabetes mellitus	3.14e-06	2.79e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.12e-06	2.77e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—HIF1A—type 2 diabetes mellitus	3.11e-06	2.76e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IRS2—type 2 diabetes mellitus	3.1e-06	2.75e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—AGT—type 2 diabetes mellitus	3.09e-06	2.75e-05	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—AKT1—type 2 diabetes mellitus	3.08e-06	2.74e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CALM1—type 2 diabetes mellitus	3.04e-06	2.7e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—LEP—type 2 diabetes mellitus	3.03e-06	2.69e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—APOE—type 2 diabetes mellitus	3.03e-06	2.69e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.02e-06	2.69e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—APOA1—type 2 diabetes mellitus	3e-06	2.66e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.99e-06	2.66e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—INS—type 2 diabetes mellitus	2.98e-06	2.65e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.94e-06	2.61e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.89e-06	2.56e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.88e-06	2.56e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.86e-06	2.54e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—SRC—type 2 diabetes mellitus	2.79e-06	2.48e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.74e-06	2.43e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.72e-06	2.41e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.7e-06	2.4e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—IL6—type 2 diabetes mellitus	2.63e-06	2.33e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.62e-06	2.32e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.62e-06	2.32e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—INS—type 2 diabetes mellitus	2.59e-06	2.3e-05	CbGpPWpGaD
Minocycline—CYCS—Metabolism—AKT1—type 2 diabetes mellitus	2.57e-06	2.28e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.55e-06	2.26e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.51e-06	2.22e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.5e-06	2.22e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.49e-06	2.21e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—RELA—type 2 diabetes mellitus	2.46e-06	2.19e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.44e-06	2.17e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—AKT1—type 2 diabetes mellitus	2.43e-06	2.15e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.38e-06	2.11e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.27e-06	2.02e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.27e-06	2.02e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.22e-06	1.97e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—RELA—type 2 diabetes mellitus	2.14e-06	1.9e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.08e-06	1.84e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—SRC—type 2 diabetes mellitus	1.94e-06	1.72e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.93e-06	1.71e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.88e-06	1.67e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IL6—type 2 diabetes mellitus	1.88e-06	1.67e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.82e-06	1.62e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.8e-06	1.6e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.73e-06	1.54e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.73e-06	1.54e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.7e-06	1.51e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—SRC—type 2 diabetes mellitus	1.68e-06	1.49e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—AKT1—type 2 diabetes mellitus	1.58e-06	1.41e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.5e-06	1.33e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.47e-06	1.31e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IL6—type 2 diabetes mellitus	1.3e-06	1.16e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.2e-06	1.07e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IL6—type 2 diabetes mellitus	1.13e-06	1.01e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.04e-06	9.27e-06	CbGpPWpGaD
